Epione Therapeutics is a biopharmaceutical company founded in 2021 in Amsterdam (NL) ready to enter clinical phase. Epione Therapeutics develops injectable biomaterial-based formulations of existing drugs for long term pain relief in chronic musculoskeletal disease. At the basis of the Epione pipeline is a versatile biomaterial platform with unique characteristics enabling up to 6 months of both small molecules and protein-based drugs. Based on extensive preclinical data sets, Epione’s leading product based on the local release of a COX-2 inhibitor is close to first-in-human clinical trials in knee osteoarthritis and chronic low back pain.